Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ADMA Biologics and certain officers, alleging securities law violations. The suit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The complaint claims the company engaged in an undisclosed related party transaction, used channel stuffing to inflate revenue, and lacked adequate internal controls, rendering its statements materially false and misleading. Investors have until August 10, 2026 to seek lead plaintiff appointment. The firm represents investors on a contingency fee basis.
ADMA Biologics IncClass action lawsuit alleging securities law violations, undisclosed related party transaction, channel stuffing, and inadequate internal controls.